These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 19930733

  • 1. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009 Aug 05; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

  • 4. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 5. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.
    Vaccine; 2009 Jul 30; 27(35):4776-83. PubMed ID: 19539578
    [Abstract] [Full Text] [Related]

  • 7. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 8. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM, Habbema JD, Mourits MJ, Coebergh JW, van Leeuwen FE.
    Ned Tijdschr Geneeskd; 2008 Sep 13; 152(37):2001-4. PubMed ID: 18825885
    [Abstract] [Full Text] [Related]

  • 9. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.
    Gynecol Oncol; 2009 Feb 13; 112(2):370-6. PubMed ID: 19041125
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.
    Vaccine; 2011 Nov 08; 29(48):8929-36. PubMed ID: 21945961
    [Abstract] [Full Text] [Related]

  • 12. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 13. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M.
    Eur J Cancer; 2011 Feb 20; 47(3):428-35. PubMed ID: 20971633
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic evaluation of human papillomavirus vaccination in developed countries.
    Brisson M, Van de Velde N, Boily MC.
    Public Health Genomics; 2009 Feb 20; 12(5-6):343-51. PubMed ID: 19684446
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Feb 20; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 19. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2011 Oct 26; 29(46):8443-50. PubMed ID: 21816193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.